Fate Therapeutics Stock Price on November 19, 2024
| FATE Stock | USD 1.66 0.02 1.19% |
Below is the normalized historical share price chart for Fate Therapeutics extending back to October 01, 2013. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Fate Therapeutics stands at 1.66, as last reported on the 26th of December, with the highest price reaching 1.68 and the lowest price hitting 1.61 during the day.
If you're considering investing in Fate Stock, it is important to understand the factors that can impact its price. Fate Therapeutics secures Sharpe Ratio (or Efficiency) of -0.15, which denotes the company had a -0.15% return per unit of risk over the last 3 months. Fate Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Fate Therapeutics' Standard Deviation of 6.53, variance of 42.7, and Mean Deviation of 5.03 to check the risk estimate we provide.
At present, Fate Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Sale Purchase Of Stock is expected to grow to about 522.2 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 54.2 M. . The current year's Price Earnings To Growth Ratio is expected to grow to 0.06, whereas Price To Sales Ratio is forecasted to decline to 5.50. Fate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of October 2013 | 200 Day MA 3.8676 | 50 Day MA 2.473 | Beta 1.879 |
Fate |
Sharpe Ratio = -0.1481
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FATE |
Estimated Market Risk
| 6.6 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fate Therapeutics by adding Fate Therapeutics to a well-diversified portfolio.
Price Book 0.5218 | Enterprise Value Ebitda (2.59) | Price Sales 14.0599 | Shares Float 98.8 M | Wall Street Target Price 6.3077 |
Related Headline
Atara Biotherapeutics Headline on 19th of November 2024
LB Pharmaceuticals Names Heather Turner as CEO to Lead its D... by finance.yahoo.com
Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for 2.7 billion LB Pharmas lead asset, LB-102, is a patent protected blood-brain barrier-optimized analog of amisulpride, a well-established antipsychotic widely used in EuropeLB-102 is designed to address both the positive and negative symptoms of schizophreniaLB Pharma expects to announce top-line data from its LB-102 Phase 2 trial in the first quarter of 2025LB Pharma is
Fate Therapeutics Valuation on November 19, 2024
It is possible to determine the worth of Fate Therapeutics on a given historical date. On November 19, 2024 Fate was worth 2.2 at the beginning of the trading date compared to the closed value of 2.18. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Fate Therapeutics stock. Still, in general, we apply an absolute valuation method to find Fate Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fate Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Fate Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.26 | 3.50 | 2.23 | 2.27 | 24,748,629 | |
11/19/2024 | 2.20 | 2.26 | 2.03 | 2.18 | 4,502,343 |
| 2.16 | 2.35 | 2.03 | 2.22 | 2,373,556 |
| Backtest Fate Therapeutics | | | Fate Therapeutics History | | | Fate Therapeutics Valuation | Previous | Next |
Fate Therapeutics Trading Date Momentum on November 19, 2024
| On November 20 2024 Fate Therapeutics was traded for 2.22 at the closing time. The top price for the day was 2.35 and the lowest listed price was 2.03 . The trading volume for the day was 2.4 M. The trading history from November 20, 2024 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 1.83% . The overall trading delta against the current closing price is 44.04% . |
Fate Therapeutics Fundamentals Correlations and Trends
By evaluating Fate Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Fate Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Fate financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Fate Therapeutics Stock history
Fate Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Fate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Fate Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Fate Therapeutics stock prices may prove useful in developing a viable investing in Fate Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 98.4 M | 54.2 M | |
| Net Loss | -253.5 M | -240.9 M |
Fate Therapeutics Quarterly Net Working Capital |
|
Fate Therapeutics Stock Technical Analysis
Fate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Fate Therapeutics Period Price Range
Low | December 26, 2024
| High |
0.00 | 0.00 |
Fate Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Fate Therapeutics December 26, 2024 Market Strength
Market strength indicators help investors to evaluate how Fate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Fate Therapeutics shares will generate the highest return on investment. By undertsting and applying Fate Therapeutics stock market strength indicators, traders can identify Fate Therapeutics entry and exit signals to maximize returns
Fate Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Fate Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Fate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Fate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.08) | |||
| Total Risk Alpha | (1.27) | |||
| Treynor Ratio | (0.37) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets |